Clinical Biofilm Studies – An Interesting Evolving Landscape

A recent article on “Agents that Prevent Biofilm Formation” captured my interest[1].  The authors reviewed the literature and mentioned many substances which have shown in-vitro efficacy in disrupting biofilm production by the main offenders, i.e., S. aureus, S. epidermidis, P. aeruginosa and K. pneumoniae. These substances come with very diverse Continue reading Clinical Biofilm Studies – An Interesting Evolving Landscape

Most Anti-Infective Guidelines Don’t Get No Respect (Let Alone Use!)

It is no secret that most existing antibiotic guidelines are not getting much use these days.  The only indications pursued with any regularity are the feasible ones: ABSSSI, cUTI, and cIAI, much less CABP.  Yes, the occasional HABP/VABP trial is being undertaken by the intrepid but no company has taken Continue reading Most Anti-Infective Guidelines Don’t Get No Respect (Let Alone Use!)

The Beauty of Science: No Need to Think About Costs When You Live in An Ivory Tower

The recently published INSIGHT trial showed that starting HIV therapy earlier rather than later has benefit for patients 1. This should not come as a surprise considering the excellent suppressive power of current triple regimens.  The trial which enrolled 4685 HIV infected patients was stopped prematurely when an interim analysis Continue reading The Beauty of Science: No Need to Think About Costs When You Live in An Ivory Tower